ArticleNeurodegenerative disease management2012
Appraisal of cognition in preclinical Alzheimer's disease: a conceptual review.
Article in Neurodegenerative disease management, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Neocortical tau burden determines the degree of cognitive impairment in individuals with Braak stage V neurofibrillary degeneration.Acta neuropathologica · 2026Article
- Longitudinal assessment of cognitive decline and resilience in high-level Alzheimer disease neuropathologic change.Alzheimer's research & therapy · 2025Article
- Primary age-related tauopathy.Acta neuropathologica · 2025Review
- Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges.Frontiers in medicine · 2024Review
- Symptomatic Profile and Cognitive Performance in Autopsy-Confirmed Limbic-Predominant Age-Related TDP-43 Encephalopathy With Comorbid Alzheimer Disease.Journal of neuropathology and experimental neurology · 2022Article
- Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches.Amyotrophic lateral sclerosis & frontotemporal degeneration · 2022Article
- Impaired Affordance Perception as the Basis of Tool Use Deficiency in Alzheimer's Disease.Healthcare (Basel, Switzerland) · 2022Article
- Differences in Symptomatic Presentation and Cognitive Performance Among Participants With LATE-NC Compared to FTLD-TDP.Journal of neuropathology and experimental neurology · 2021Article
- Cognitive trajectory in mild cognitive impairment due to primary age-related tauopathy.Brain : a journal of neurology · 2020Article
- Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimer's Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment.Journal of Alzheimer's disease : JAD · 2020Article
- "New Old Pathologies": AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS).Journal of neuropathology and experimental neurology · 2016Review
- Sensitivity to change and prediction of global change for the Alzheimer's Questionnaire.Alzheimer's research & therapy · 2015Article
- Primary age-related tauopathy (PART): a common pathology associated with human aging.Acta neuropathologica · 2014Article
- Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology.Neurology · 2014Article
- Subjective memory complaints, cognitive performance, and psychological factors in healthy older adults.American journal of Alzheimer's disease and other dementias · 2013Article
- Clinical and demographic factors modify the association between plasma phosphorylated tau-181 and cognition.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- The Utility of the National Alzheimer's Coordinating Center's Database for the Rapid Assessment of Evolving Neuropathologic Conditions.Alzheimer disease and associated disordersArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Biomarker evidence and clinical observations support the hypothesis that there is a diagnosable condition termed preclinical Alzheimer's disease (AD). Recently, a workgroup convened under the auspices of the National Institute on Aging and the Alzheimer's Association proposed a framework for defining preclinical AD. The definition was based on the presence of biomarkers that are indicative of the AD pathophysiological process. In the context of abnormal AD biomarkers, the workgroup postulated that 'subtle cognitive changes' occurred as well. Based on studies of genetically at-risk individuals and those destined to become demented, who were observed while still cognitively normal, low performance on learning and memory functions may be the earliest cognitive manifestations of preclinical AD, at the group level at least. It is not clear whether subtle cognitive decline can be detected reliably on an individual basis. Preclinical AD cognitive changes could be diagnosed by traditional neuropsychological testing, computerized testing, assessments of subjective memory loss, assessments of levels of participation in cognitively stimulating activities and direct measurement of activity using recently developed monitoring technology. Confounding effects of normal aging, test-retest variability, variations in educational attainment, as well as the presence of other brain diseases make diagnosing cognitive decline due to preclinical AD challenging.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.